Stay ConnectedInterviews with the scientists, founders and investors driving Human 3 – the next epoch of health, wellbeing and performance.
Topics include brain-computer interfaces, genetic medicine, psychedelics, longevity, AI and more.
Hosted by Brom Rector and Sam Tabone – founders of XEIA Venture Partners, a venture capital fund investing in Human 3.
More at www.xeiavp.com
Copyright: © Brom Rector and Empath Ventures
Dillan DiNardo, the founder and CEO of Mindstate Design Labs, a drug development company using AI to enable the precision design of altered states of consciousness joins the podcast to discuss the state of psychedelics, AI, consciousness, why Marc Andreessen hates psychedelics, and the intersection of all these things. Follow Brom on Twitter: https://twitter.com/therealbrom Learn more about Mindstate: https://www.mindstate.design/ Brom is the founder of focalpoint partners: https://www.focalpointlp.com/
Today’s guests are MJ Antonini & Nicki Driscoll, the founders of NeuroBionics, a neurotech startup out of MIT. NeuroBionics is making Deep Brain Stimulation minimally invasive though the development of nano fibers that are 10X thinner than traditional Deep Brain Stimulation leads - allowing them to be inserted endovascularly into the brain. Check out NeuroBionics at https://neurobionics.io/
Lars Wilde is the cofounder of Pangea Bio - startup that uses AI to identify natural compounds and traditional remedies that may have medical applications. Prior to starting Pangea, Lars cofounded Compass Pathways and ATAI life sciences, both of which IPOd on the NASDAQ.
Can a succulent plant from South Africa treat premature ejaculation? John Boghossian and Dr Ryan Protzko from Kadence Bio think so.
Can brain implants treat your depression? Ok, technically this would be a skull implant, not a brain implant - but still!
Jacob Robinson from Motif Neurotech discusses the future of minimally invasive electronic medicine from mental health and beyond.
This is a crossover episode from the Business Trip podcast.
Will MDMA and psychedelic therapy be affordable? There are lots of questions about the economic and financial future of psychedelic therapies. How much will they cost? Will insurance cover them? And more fundamentally, how does one even begin to quantify the value of a psychedelic experience? Today’s guest, Elliot Marseille, PhD is here to explore all these questions and more. Dr. Marseille is a leading expert on the economics of the emerging psychedelic-assisted therapies. He is the founding Director of the UC Berkeley's Global Initiative for Psychedelic Science Economics (GIPSE), a network of health economists and health services researchers dedicated to realizing the potential of psychedelic therapies for high-priority mental health conditions. Through the application of policy-relevant economic analyses, GIPSE seeks to enhance the efficiency of service delivery, and increase access to these promising therapies. Follow Dr. Marseille's work: https://cghdde.berkeley.edu/projects/global-initiative-psychedelic-science-economics-gipse
🤖 ChatGPT & Dall-E today - misinformation, bias & worker displacement tomorrow. In a world where artificial intelligence is becoming increasingly advanced, it's more important than ever to ensure that AI systems are aligned with our values and behave in ways that are safe for humanity. But what exactly does it mean to align an AI system, and how do we go about ensuring its safety?
Here to answer these questions and more (including the most important question: will AIs take psychedelics?) is Ramsay Brown. Ramsay is the Founder of the AI Responsibility Lab (AIRL). AIRL builds venture-scale deep tech solutions for AI Safety and AI Resilience. AIRL's flagship product, Mission Control, integrates Responsible AI training, AI Risk Management, and AI Governance orchestration to drive fairness, explainability, and trust throughout the entire AI lifecycle.
Check out AIRL here: https://www.takecontrol.ai/
Ramsay on Twitter: https://twitter.com/_ramsaybrown
Brom on twitter: https://twitter.com/therealbrom
5:30 - What are the major concerns in AI safety?
10:30 - Examples of AI gone bad
16:00 - What is the hardest part of AI alignment?
21:00 - What is Ramsay’s unique angle on AI alignment?
24:00 - Is the world ready for conversations about responsible AI?
25:30 - Who is responsible for responsible AI?
32:00 - What regulations would Ramsay put into place?
41:00 - Eliezer Yudkowsky
47:00 - The era of synthetic labor
55:00 - The Turing Test is a red herring
1:04:00 - What jobs are safe from the AI takeover?
1:14:00 - Will machines do psychedelics?
Zach Haigney is the author of The Trip Report, a newsIetter that covers the emerging psychedelic science, medicine, and policy landscape. In this conversation, Zach and Brom discuss emerging trends, questions and hot topics in the psychedelics industry including:
We also discuss The Trip Report's recent acquisition by Beckley Waves.
You can check out The Trip Report here: https://thetripreport.substack.com/
Follow Zach on Twitter: https://twitter.com/zach_haigney
Follow Brom on Twitter: https://twitter.com/therealbrom
Make sure to subscribe to the show!
Sam Banister is a medicinal chemist and co-founder of Psylo. Psylo is an Australian psychedelic biotech company using machine learning assisted drug design techniques to developing novel psychedelic medicines to treat mental illness.
Sam is here to help us understand how new chemical entities are reshaping the psychedelic field; how novel psychedelic molecules are made, and how new chemical entities are going to play a dominant role in the future of psychedelic medicine.
Make sure to subscribe to the show!
Follow Brom on twitter: https://twitter.com/therealbrom
Follow Sam on twitter: https://twitter.com/samuel_b_phd
Brom's VC Fund: https://www.empath.vc
Highlighted Timestamps:
06:12 - Are next generation psychedelics taking over in 10 years?
16:10 - What is the process like for creating a new chemical entities?
50:39 - Psychedelics vs Cannabis: New drug discoveries
Mendel Kaelen is the CEO of Wavepaths. Prior to founding Wavepaths, Mendel Kaelen worked as a PhD and postdoctoral neuroscientist at Imperial College London since 2012, where his research was the one of the first to demonstrate music’s central role in psychedelic therapies. Wavepaths is a software platform that generates personalized, optimal music for psychedelic therapy.
0:00 - Why work on music and psychedelics?
3:30 - Highlights of Mendel’s academic career.
7:30 - Is there a universal “best” music for psychedelic therapy? How to design a psychedelic therapy playlist.
11:30 - What does the importance of music personalization mean for group psychedelic sessions?
16:00 - Should music for psychedelics be “familiar” to the patient, or novel?
20:00 - Vocals vs no vocals? It’s not that simple.
23:00 - Directive vs non-directive and concrete vs fluid music.
25:00 - Is the “right” music for psychedelics consistent across different drugs?
28:00 - How did Mendel switch from academia to startup founder.
30:30 - What is Wavepaths?
35:30 - Who is Wavepaths for?
37:00 - How do you sell music for psychedelic therapy?
39:00 - Surprising insights from Wavepaths customers?
43:30 - How does Wavepaths use biofeedback?
46:00 - Wavepaths direct to consumer.
49:45 - Startup life vs academia.
51:00 - Virtual reality and psychedelic therapy.
Our TOPPODCAST Picks 
